GuidelineEuropean thyroid journal2026
2026 ETA guideline on interference in immunoassay measurements used in assessment of thyroid function.
Guideline in European thyroid journal, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Although measurement of thyroid hormones (THs), TSH and thyroid autoantibodies, is usually straightforward, erroneous results are occasionally generated, raising the possibility of incorrect or delayed diagnoses, unwarranted investigations, and provision of inappropriate treatments. Assay interference can be acquired (e.g. antibodies), genetic (e.g. variant TH-binding proteins), or pharmaceutical (e.g. displacing agents and biotin) in nature. In those with discordant thyroid function, assay interference must be excluded prior to the diagnosis of rare inherited (resistance to thyroid hormone) or tumoural conditions (TSHoma). Liaison between the clinician and clinical biochemistry teams is essential when assay interference is being investigated; appropriate further biochemical testing depends on the clinical picture, initial biochemistry, and local biochemical expertise. In a subset of cases, access to a regional centre where patients can be clinically assessed, in conjunction with performance of specialised clinical laboratory testing (biochemical, +/- genetic), may be required. When assay interference is identified, clear communication with the patient (ideally aided by reliable, accessible patient literature) and documentation to their physician are necessary. Professionals must stay updated on advances in testing and be alert for evolving assay interferences. An accompanying plain language summary is intended to provide an accessible overview of the key messages and recommendations contained in this guideline for non-specialist readers, including patients, carers, healthcare professionals outside the speciality, and the wider public.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.